<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1718">
  <stage>Registered</stage>
  <submitdate>17/10/2007</submitdate>
  <approvaldate>17/10/2007</approvaldate>
  <nctid>NCT00546325</nctid>
  <trial_identification>
    <studytitle>REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents</studytitle>
    <scientifictitle>REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents</scientifictitle>
    <utrn />
    <trialacronym>REASSURE</trialacronym>
    <secondaryid>RIMON_L_01661</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rimonabant
Treatment: drugs - Placebo

Experimental: 1 - Rimonabant

Placebo Comparator: 2 - Placebo


Treatment: drugs: Rimonabant
White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast

Treatment: drugs: Placebo
Matching placebo tablets. Once daily before breakfast

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change in HbA1c between both placebo and rimonabant group.</outcome>
      <timepoint>From baseline to week 48</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of participants reaching the treat-to-target objective of HbA1c = 6.5% and = 7.0%</outcome>
      <timepoint>From the beginning to the end of the study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Percentage of participants responding to treatment</outcome>
      <timepoint>From the beginning to the end of study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rate of asymptomatic, symptomatic, and severe hypoglycaemia</outcome>
      <timepoint>From the beginning to the end of the study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in physical examinations, vital signs, laboratory parameters, adverse events</outcome>
      <timepoint>From the beginning to the end of the study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in insulin sensitivity, fasting plasma glucose, hypoglycaemia rate.</outcome>
      <timepoint>From the beginning to the end of the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in BMI, waist and hip circumference, waist/hip ratio, weight</outcome>
      <timepoint>From the beginning to the end of the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Quality of Life</outcome>
      <timepoint>From the beginning to the end of the study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in lipid measures: HDL (High Density Lipoprotein), LDL (Low-Density Lipoprotein), TG (Triglycerides), TC (Total Cholesterol), ApoB (Apolipoprotein B)</outcome>
      <timepoint>From administration of drug till end of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in adiponectin, fasting insulin, Blood Pressure, concomitant medications, health resource use, CRP (C Reactive Protein), ALT (Alanine Aminotransferase), albumin/creatinine ratio</outcome>
      <timepoint>From administration of drug to end of study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>List of Inclusion and</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

        Inclusion Criteria:

          -  History of Type 2 diabetes

          -  HbA1c between 7% to 9% (inclusive)

          -  BMI = 27kg/m² and BMI = 40kg/m²

          -  Currently taking Metformin and Sulfonylurea.

        

          -  Uncontrolled serious psychiatric illness such as major depression

          -  Current use of antidepressants

          -  Severe renal impairment (creatinine clearance less than 30ml/min)

          -  Severe hepatic impairment known by investigator or Aspartate Aminotransferase and/or
             Alanine Aminotransferase &gt; 3 times Upper Limit Normal

          -  Patient treated for epilepsy

          -  Pregnant or breast-feeding women

          -  Women of childbearing potential not protected by effective contraception

          -  Hypersentivity/intolerance to rimonabant or any of the excipents

          -  Presence of any condition, current or anticipated that in the investigator's opinion
             would compromise the patient's safety

          -  Use of insulin for longer than 1 week within 4 weeks prior to screening

          -  Chronic use of systemic corticosteriods

          -  Use of glitazone therapy, glucagon-like peptide or dipeptidyl peptidase IV

          -  History of drug or alcohol abuse wihtin the last three years

          -  Heart failure class III-IV (New York Heart Association classification)

          -  Severe hypertension

          -  Adminstration of the following medications: phentermine, amphetamines, orlistat,
             sibutramine, herbal remedies

          -  Use of non-lipid agents known to affect lipid metabolism: retinoids, antiretrovirals,
             hormone replacement therapy containing estrogens, cyclosporin, thiazolidinediones
             (glitazones), fish oils, plant sterols

          -  Use of ketoconazole, itraconazole, ritonavir, clarithromycin, rifampicin, phenytoin,
             phenobarbitone, carbamazepine or St John's Wort

          -  Participation in a clinical study within the 4 weeks prior to randomisation

          -  Patients involved in an existing weight loss program

          -  Presence of chronic hepatitis

          -  Use, or misuse, of substances of abuse

          -  Marijuana or hashish users

          -  History of gastrointestinal surgery for weight loss purposes or who are scheduled for
             such surgery within the duration of their expected participation in this study

          -  History or presence of bulimia or laxative abuse

          -  Non-English speaking

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>358</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis Administrative Office - North Ryde</hospital>
    <postcode> - North Ryde</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Primary:

      To assess the effects of rimonabant on HbA1c in patients with Type 2 diabetes who are
      overweight or obese (Body Mass Index (BMI) &gt; 27 kg/m² and BMI &lt; 40 kg/m²), have uncontrolled
      HbA1c (7.0% - 9.0% inclusive) and are currently on maximal tolerated doses of two Oral Anti
      Diabetic medications - Metformin (Met) and Sulfonylurea (SU).

      Secondary:

      To assess the effects of rimonabant on Anthropometric measures, Glucose measures, Lipid
      measures, Other measures and changes in quality of life</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00546325</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David WHEATLEY</name>
      <address>Sanofi</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>